ProKidney Corp Announces Successful Closing of $140 Million Public Offering and Registered Direct Offering
ProKidney Corp, a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease, has recently completed a significant financial milestone. The company has successfully closed a public offering and concurrent registered direct offering, raising a total of $140 million.
In the public offering, ProKidney sold 46,886,452 Class A ordinary shares to the public at a price of $2.42 per share. This includes an additional 4,142,232 Class A ordinary shares that were sold as a result of the underwriters exercising their option to purchase additional shares. The total value of the shares sold in the public offering, before applicable underwriting discounts and commissions, amounts to $113.5 million.
In the concurrent registered direct offering, ProKidney sold 11,030,574 Class A ordinary shares to certain investment entities at the same price of $2.42 per share. This transaction was conducted through share purchase agreements and generated a total of $26.7 million.
The successful completion of these offerings is a significant achievement for ProKidney Corp, as it provides the company with substantial funds to further its research and development efforts in the field of chronic kidney disease. With its late clinical-stage cellular therapeutics technology, ProKidney aims to address the unmet medical needs of patients suffering from this debilitating condition.
It is important to note that ProKidney Corp has faced challenges in the past. From the third quarter of 2022 to the third quarter of 2023, the company recorded a cumulative net loss of $222 million. This resulted in a negative return on investment (ROI) of -47.12%. However, the successful completion of these recent offerings indicates investor confidence in ProKidney’s potential and willingness to support its mission.
Comments